Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (<i>FGFR1</i>) rearrangement

Umino, Kento; Fujiwara, Shin-ichiro; Ikeda, Takashi; Toda, Yumiko; Ito, Shoko; Mashima, Kiyomi; Minakata, Daisuke; Nakano, Hirofumi; Yamasaki, Ryo; Kawasaki, Yasufumi; Sugimoto, Miyuki; Yamamoto, Chiyo; Ashizawa, Masahiro; Hatano, Kaoru; Sato, Kazuya; Oh, Iekuni; Ohmine, Ken

doi:10.1080/10245332.2018.1446279

Cited by 28 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Umino et al, show a 1-year overall survival of 43.15% in MPN, MDS and LBL with FGFR1 rearrangement. 5 Authors could assess response to treatment by cytogenetics and MRD by flow cytometry in two cases. Strikingly there was a dramatic reduction in positive metaphases in case 1.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4] A study showed a 1-year overall survival (OS) of 43.15% in MPN, MDS and LBL with FGFR1 gene rearrangements. 5 In this study, the authors present four patients with FGFR1 rearrangements where three cases presented as Tcell lymphoblastic lymphoma (a rare form of aggressive non-Hodgkin's lymphoma.) and one case as MPAL.…”

Section: Introductionmentioning

confidence: 99%

“…So far, approximately 15 FGFR1 translocation partner genes have been identified-ZMYM2, CNTRL, FGFR1OP1, BCR, FGFR1OP2, TIFI, MYO18A, CPSF6, LRRFIP1, NUP98, HERVK, CUX1, TPR, RUNX1 in AML, MPN with eosinophilia, aCML, MPN+T-ALL, PV, B-ALL, MPAL, MDS, systemic mastocytosis and other types of leukemias. [5][6][7] According to literature, t(8;13)(p11;q12) (i.e. FGFR1/ ZMYM2) is most common and is seen in 50% cases, followed by t(8;22)(p11;q11) (i.e.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical, hematological and cytogenetic profile in fibroblast growth factor receptor 1 rearranged hematoloymphoid malignancies

et al. 2020

View full text Add to dashboard Cite

The background of this study is FGFR1 belongs to a family of four, high-affinity receptor tyrosine kinase and is a legitimate oncogene associated with uterine, cervical, prostate, bladder, colorectal and lung cancers. It is rarely concomitant in myeloid and lymphoid neoplasms but has an aggressive clinical course with a high mortality rate when present. Cytogenetic abnormalities involving the FGFR1 gene is most frequently observed in AML, MPN with eosinophilia, T-ALL and T-LBL with ZMYM2 gene being the most common fusion partner. Methods of this study was to authors report a series of 4 cases with FGFR1 rearrangements. Results is three patients presented as T-cell Lymphoblastic lymphoma (T-LBL) and one as mixed phenotype acute leukemia (MPAL). The T-LBL cases harboured the FGFR1/ ZMYM2 fusion and the MPAL case harbored the CNTRL/FGFR1 fusion as identified by conventional cytogenetics and confirmed by molecular studies. Conclusion is authors herewith describe the clinical, biochemical, molecular and cytogenetic features observed in these cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical, hematological and cytogenetic profile in fibroblast growth factor receptor 1 rearranged hematoloymphoid malignancies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…2 Patients carrying this fusion present leukocytosis with features resembling chronic myeloid leukemia or, less frequently, B-lymphoblastic lymphoma, mixed-phenotype B/myeloid acute leukemias, or T/B/myeloid mixed-phenotype acute leukemias. 3 The disease is characterized by an aggressive evolution and poor prognosis. Chemotherapy never obtains complete remission (CR); the only chance for long-term survival consists of allogeneic hematopoietic stem cell transplantation (HSCT), which is strongly recommended.…”

Section: Monitoring Minimal Residual Disease By Ddpcr In Acute Lymphomentioning

confidence: 99%

“…Flow cytometric analysis of cerebrospinal fluid showed the involvement of central nervous system by leukemic cell infiltration. Conventional cytogenetic analysis of G-banded bone marrow metaphase cells showed the following karyotype: 46,XX,t(8;22)(q11;q11)[17]/46,XX[3].Fluorescence in situ hybridization (FISH) analysis, performed as previously reported 7,8 on bone marrow sample of the onset using bacterial artificial chromosome (BAC) clones specific for the BCR (RP11-164N13) and FGFR1 (RP11-957P17 and RP11-350N15) genes, revealed a BCR-FGFR1 rearrangement. The presence of the BCR-FGFR1 fusion gene was confirmed by RT-PCR, according to the published methods.…”

mentioning

confidence: 99%

Monitoring minimal residual disease by ddPCR in acute lymphoblastic leukemia associated with the FGFR1 gene rearrangement

Coccaro

Tota

Zagaria

et al. 2018

Int J Lab Hematology

View full text Add to dashboard Cite

The international consensus classification of eosinophilic disorders and systemic mastocytosis

et al. 2023

View full text Add to dashboard Cite

Based on new data and increased understanding of disease molecular genetics, the international consensus classification (ICC) has made several changes in the diagnosis and classification of eosinophilic disorders and systemic mastocytosis. Myeloid/lymphoid neoplasms with eosinophilia (M/LN‐eo) and gene rearrangements have been renamed as M/LN‐eo with tyrosine kinase gene fusions (M/LN‐eo‐TK). The category has been expanded to include ETV6::ABL1 and FLT3 fusions, and to accept PCM1::JAK2 and its genetic variants as formal members. The overlaps and differences between M/LN‐eo‐TK and BCR::ABL1‐like B‐lymphoblastic leukemia (ALL)/de novo T‐ALL sharing the same genetic lesions are addressed. Besides genetics, ICC for the first time has introduced bone marrow morphologic criteria in distinguishing idiopathic hypereosinophilia/hypereosinophilic syndrome from chronic eosinophilic leukemia, not otherwise specified. The major diagnostic criteria for systemic mastocytosis (SM) in the ICC remain largely based on morphology, but several minor modifications/refinements have been made in criteria related to diagnosis, subclassification, and assessment of disease burden (B‐ and C‐findings). This review is to focus on the ICC updates related to these disease entities, illustrated through changes related to morphology, molecular genetics, clinical features, prognosis, and treatment. Two practical algorithms are provided in navigating through the diagnosis and classification systems of hypereosinophilia and SM.

show abstract

Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement

Abstract: The further accumulation of clinical data is needed to determine the optimal therapeutic approach for these neoplasms.

Cited by 28 publications

References 42 publications

Clinical, hematological and cytogenetic profile in fibroblast growth factor receptor 1 rearranged hematoloymphoid malignancies

Clinical, hematological and cytogenetic profile in fibroblast growth factor receptor 1 rearranged hematoloymphoid malignancies

Monitoring minimal residual disease by ddPCR in acute lymphoblastic leukemia associated with the FGFR1 gene rearrangement

The international consensus classification of eosinophilic disorders and systemic mastocytosis

Contact Info

Product

Resources

About